The new molecular kits have been developed to provide quantitative detection of viral DNA extracted from blood plasma and urine (BKV kit), or blood plasma and whole blood (EBV kit) from immunocompromised patients. The kits have been designed to run using the Roche LightCycler® 480 II PCR instrument. Quantification Standards in the kits are calibrated against the First World Health Organization International Standards for Virus Nucleic Acid Amplification Techniques (NIBSC code 14/212), and demonstrate the kits have strong levels of sensitivity and specificity performance as well as reproducibility.
The genesig Real-Time PCR BKV Kit (CE), and genesig Real-Time PCR EBV Kit (CE) allow monitoring of viral load alongside the patients medication regimes to help increase the likelihood of successful transplantation.
The genesig Real-Time PCR BKV Kit (CE) is intended to be used on the Roche LightCycler® 480 II PCR platform to achieve quantitative detection of BKV DNA extracted from blood plasma and urine from immunocompromised patients in association with the designated extraction instrument and kits:
The genesig Real-Time PCR EBV Kit (CE) is intended to be used on the Roche LightCycler® 480 II PCR platform to achieve quantitative detection of EBV DNA extracted from whole blood and blood plasma from immunocompromised patients in association with the designated extraction instrument and kits:
The kits include an Internal Control to identify possible PCR inhibition, to measure extraction purity and to confirm the integrity of PCR run.
Quantification Standards (QS) are included in the kits which are calibrated against the First World Health Organization International Standards for Virus Nucleic Acid Amplification Techniques (NIBSC code 14/212). The Quantitation Standards demonstrate that the kits have strong levels of sensitivity and specificity performance, as well as allowing harmonisation of results across labs. The Quantification Standards can be used individually as positive controls, or together to generate a standard curve which can be used to determine the concentration of specific viral DNA in a sample.
BK virus (BKV) is a polyomavirus and Epstein-Barr Virus (EBV) is a gamma herpesvirus, both viruses can cause disease in humans.
BKV primary infection usually occurs in childhood leading to symptoms similar to a common cold followed by lifelong latent infection. BKV causes disease during transplantation, including BKV-associated nephropathy (BKVN) in kidney transplantation which is an increasing problem and leads to renal injury and graft loss. BKV also leads to hemorrhagic cystitis in hematopoietic cell transplantation (HCT).
EBV primary infection usually occurs in childhood leading to asymptomatic viremia followed by lifelong latent infection, while later infection can lead to mononucleosis. EBV has oncogenic potential and is associated with a range of cancers, including Post-Transplant Lymphoproliferative disorder (PTLD) in post-transplant recipients.
To prevent the post-transplantation diseases caused by both viruses there is increasing monitoring for BKV and EBV DNAemia after transplantation and in patients undergoing immunosuppression.
The analytical sensitivity was defined as the lowest concentration of analyte that could be reliably detected with 95% confidence. This was assessed across 3 clinical specimens over 3 days producing at least 30 replicates for each sample type and extraction system combination.
genesig Real-Time PCR BKV Kit (CE) analytical sensitivity:
genesig Real-Time PCR EBV Kit (CE) analytical sensitivity:
PRODUCT DESCRIPTION KIT SIZES CATALOGUE NO.
genesig Real-Time PCR BKV Kit (CE) 100 reactions Z-Path-BKV-CE
genesig Real-Time PCR EBV Kit (CE) 100 reactions Z-Path-EBV-CE
Kit includes: oasig® Lyophilised qPCR Master Mix, Primer & Probe Mix, 4 Quantitation Standards, Internal Extraction Control, No Template Control, Resuspension Buffers
The genesig Real-Time PCR BKV Kit (CE), and genesig Real-Time PCR EBV Kit (CE), are CE-IVD marked and intended for in vitro diagnostic use in Europe.
